Aliases & Classifications for Lentigines

MalaCards integrated aliases for Lentigines:

Name: Lentigines 57 54
Lentigo 71

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal dominant


HPO:

31
lentigines:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM® 57 150900
MedGen 41 C0023321
UMLS 71 C0023321

Summaries for Lentigines

MalaCards based summary : Lentigines, also known as lentigo, is related to noonan syndrome with multiple lentigines and leopard syndrome 2. An important gene associated with Lentigines is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11), and among its related pathways/superpathways are Sertoli-Sertoli Cell Junction Dynamics and Aldosterone synthesis and secretion. The drugs Aminolevulinic acid and Photosensitizing Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and heart, and related phenotypes are nystagmus and abnormality of the skin

Wikipedia : 74 A lentigo (/lɛnˈtaɪɡoʊ/) (plural lentigines, /lɛnˈtɪdʒɪniːz/) is a small pigmented spot on the skin with... more...

More information from OMIM: 150900

Related Diseases for Lentigines

Diseases related to Lentigines via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 155)
# Related Disease Score Top Affiliating Genes
1 noonan syndrome with multiple lentigines 32.3 RAF1 PTPN11 BRAF
2 leopard syndrome 2 32.1 RAF1 PTPN11
3 leopard syndrome 1 31.8 RAF1 PTPN11 BRAF
4 melanocytic nevus syndrome, congenital 31.2 PRKAR1A MC1R
5 noonan syndrome 1 31.0 RAF1 PTPN11 BRAF
6 pseudo-turner syndrome 30.2 RAF1 PTPN11 BRAF
7 hypertelorism 29.9 RAF1 PTPN11 BRAF
8 pulmonary valve stenosis 29.9 PTPN11 BRAF
9 hypertrophic cardiomyopathy 29.6 RAF1 PTPN11 BRAF
10 skin melanoma 29.4 RAF1 MC1R BRAF
11 skin carcinoma 29.2 RAF1 MC1R BRAF
12 rasopathy 29.1 RAF1 PTPN11 BRAF
13 leukemia, chronic myeloid 29.0 RAF1 PTPN11 BRAF
14 melanoma, cutaneous malignant 1 28.9 RAF1 MC1R BRAF
15 gastrocutaneous syndrome 11.4
16 carney complex variant 11.3
17 leopard syndrome 3 11.3
18 lentiginosis, inherited patterned 11.1
19 uv-sensitive syndrome 11.0
20 dyschromatosis universalis hereditaria 1 10.9
21 spastic paraplegia 23, autosomal recessive 10.9
22 legius syndrome 10.9
23 dowling-degos disease 1 10.6
24 melanoma 10.3
25 keratosis 10.2
26 peutz-jeghers syndrome 10.2
27 branchiootic syndrome 1 10.2
28 pustulosis of palm and sole 10.2
29 psoriasis 10.2
30 neurofibromatosis 10.1
31 atrial standstill 1 10.0
32 vitiligo-associated multiple autoimmune disease susceptibility 6 10.0
33 vitiligo-associated multiple autoimmune disease susceptibility 1 10.0
34 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
35 carney complex, type 1 10.0
36 mycosis fungoides 10.0
37 gastrointestinal stromal tumor 10.0
38 sensorineural hearing loss 10.0
39 dermatitis 10.0
40 pituitary adenoma 10.0
41 actinic keratosis 10.0
42 noonan syndrome 3 10.0 RAF1 PTPN11
43 juvenile xanthogranuloma 9.9 PTPN11 BRAF
44 thyroid tumor 9.9 PRKAR1A BRAF
45 pectus excavatum 9.9
46 cryptorchidism, unilateral or bilateral 9.9
47 dermatitis, atopic 9.9
48 becker nevus syndrome 9.9
49 alacrima, achalasia, and mental retardation syndrome 9.9
50 dyschromatosis universalis hereditaria 9.9

Graphical network of the top 20 diseases related to Lentigines:



Diseases related to Lentigines

Symptoms & Phenotypes for Lentigines

Human phenotypes related to Lentigines:

31
# Description HPO Frequency HPO Source Accession
1 nystagmus 31 HP:0000639
2 abnormality of the skin 31 HP:0000951

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Eyes:
nystagmus

Skin:
lentigines

Clinical features from OMIM®:

150900 (Updated 05-Mar-2021)

GenomeRNAi Phenotypes related to Lentigines according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 9.58 BRAF
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 9.58 PTPN11
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 9.58 PTPN11
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-138 9.58 PTPN11
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-149 9.58 PTPN11 RAF1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-161 9.58 RAF1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.58 BRAF
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.58 BRAF
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 9.58 PTPN11
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-194 9.58 BRAF
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.58 RAF1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.58 BRAF
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 9.58 BRAF
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 9.58 BRAF
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-37 9.58 PTPN11
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-47 9.58 PTPN11
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.58 BRAF

MGI Mouse Phenotypes related to Lentigines:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.89 BRAF MC1R PRKAR1A PTPN11 RAF1
2 craniofacial MP:0005382 9.88 BRAF MC1R PRKAR1A PTPN11 RAF1
3 hematopoietic system MP:0005397 9.83 BRAF MC1R PRKAR1A PTPN11 RAF1
4 immune system MP:0005387 9.8 BRAF MC1R PRKAR1A PTPN11 RAF1
5 integument MP:0010771 9.77 BRAF MC1R PRKAR1A PTPN11 RAF1
6 hearing/vestibular/ear MP:0005377 9.76 BRAF MC1R PTPN11 RAF1
7 liver/biliary system MP:0005370 9.62 BRAF PRKAR1A PTPN11 RAF1
8 muscle MP:0005369 9.56 BRAF PRKAR1A PTPN11 RAF1
9 neoplasm MP:0002006 9.55 BRAF MC1R PRKAR1A PTPN11 RAF1
10 pigmentation MP:0001186 9.26 BRAF MC1R PRKAR1A PTPN11
11 respiratory system MP:0005388 8.92 BRAF PRKAR1A PTPN11 RAF1

Drugs & Therapeutics for Lentigines

Drugs for Lentigines (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4 106-60-5 137
2 Photosensitizing Agents Phase 4
3
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
4 Adjuvants, Immunologic Phase 2, Phase 3
5 Immunologic Factors Phase 2, Phase 3
6 interferons Phase 2, Phase 3
7
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 2 67-73-2 6215
8
Hydroquinone Approved, Investigational Phase 2 123-31-9 785
9
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
10
Pembrolizumab Approved Phase 2 1374853-91-4
11
Ipilimumab Approved Phase 2 477202-00-9
12
nivolumab Approved Phase 2 946414-94-4
13
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
14
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
15
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
16
Cediranib Investigational Phase 2 288383-20-0 9933475
17
Maleic acid Experimental Phase 2 110-16-7 444266
18 Keratolytic Agents Phase 2
19 Imatinib Mesylate Phase 2 220127-57-1 123596
20 Angiogenesis Inhibitors Phase 2
21 Antibodies Phase 2
22 Immunoglobulins Phase 2
23 Antibodies, Monoclonal Phase 2
24 Antineoplastic Agents, Immunological Phase 2
25 Protein Kinase Inhibitors Phase 2
26
Neomycin Approved, Vet_approved 1404-04-2 8378
27
Petrolatum Approved, Investigational 8009-03-8
28
Clobetasol Approved, Experimental, Investigational 25122-46-7, 25122-41-2 32798 5311051
29
Tazarotene Approved, Investigational 118292-40-3 5381
30
Tetracaine Approved, Vet_approved 94-24-6 5411
31
Lidocaine Approved, Vet_approved 137-58-6 3676
32
Prilocaine Approved 721-50-6 4906
33
Chlorhexidine Approved, Vet_approved 55-56-1 9552079 2713
34 Antibiotics, Antitubercular
35 Anti-Bacterial Agents
36 Sunscreening Agents
37 Mitogens
38 Emollients
39 Anti-Inflammatory Agents
40 Hormones
41 Hormone Antagonists
42 glucocorticoids
43 Dermatologic Agents
44 Sodium Channel Blockers
45 Diuretics, Potassium Sparing
46 Anesthetics
47 Anesthetics, Local
48 Anti-Arrhythmia Agents
49 Chlorhexidine gluconate
50 Hemostatics

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
2 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
3 A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails Recruiting NCT02394132 Phase 3 Imiquimod
4 Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face Active, not recruiting NCT01720407 Phase 3 Imiquimod cream + surgery;Placebo + surgery
5 An Open Monocentric Pilot Study to Investigate the Potential of Imiquimod 5% Cream to Detect Residual and to Prevent Recurrence of Lentigo Maligna After Surgical Excision Active, not recruiting NCT01088737 Phase 2, Phase 3 Imiquimod
6 Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face - Study PICAMEL Unknown status NCT02723721 Phase 2 Picato gel
7 Solar Lentigines Treatment With the Triple Combination Cream (Hydroquinone 4%, Tretinoin 0.05%, and Fluocinolone Acetonide 0.01%). Randomized, Double Blind, Controlled Trial. Completed NCT00975312 Phase 2 Triple combination cream;Tretinoin 0.05%
8 Efficacy and Side Effects of Q-Switched Ruby Laser Treatment of Solar Lentigines in Two Different Fitzpatrick Skin Types II and IV Completed NCT00386204 Phase 2
9 A Phase II Study of AZD2171 in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma Completed NCT00243061 Phase 2 cediranib maleate
10 A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin. Completed NCT00424515 Phase 2 Imatinib
11 A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Completed NCT00577382 Phase 2 Sunitinib
12 A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma Completed NCT01395121 Phase 2 nilotinib
13 A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT Completed NCT00470470 Phase 2 imatinib mesylate
14 A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma Completed NCT00788775 Phase 2 Nilotinib
15 An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma Recruiting NCT02875132 Phase 2 pembrolizumab
16 A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma Recruiting NCT03698019 Phase 2
17 A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Recruiting NCT04511013 Phase 2 Binimetinib;Encorafenib
18 A Phase II Trial of SCH 727965 (NSC 747135) in Patients With Stage IV Melanoma Active, not recruiting NCT00937937 Phase 2 Dinaciclib
19 A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy Active, not recruiting NCT02978443 Phase 2 Nivolumab;Ipilimumab
20 Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma Terminated NCT01120275 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
21 A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma Terminated NCT01092728 Phase 2 Dasatinib
22 A Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD) Recruiting NCT03025256 Phase 1
23 Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011 on Solar Lentigines by Harmonic Generation Microscopy Unknown status NCT01249469
24 Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion. Unknown status NCT01136629
25 Safety and Efficacy of a Triple Combination Cream as Adjuvant Treatment of Solar Lentigines With Cryotherapy. Completed NCT01778179 Tri-luma
26 Comparative Study Investigating the Therapy of of Solar Lentigines With the Q-switched SINON Rubin 694nm Laser Versus Pigmanorm® Cream Completed NCT02153697 Pigmanorm Cream
27 A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy Completed NCT04704245 epidermal growth factor (EGF)-containing ointment;Vehicle ointment
28 Prospective Clinical Trial to Assess the Performance of a Cyto-selective Cryotherapye "CRYOBEAUTY MAINS ET DECOLLETE" Compared With Liquid Nitrogen Cryotherapy in the Treatment of Solar Lentigines in 30 Patients Completed NCT03225729
29 Study for the RevLite Laser System for Facial Solar Lentigines Completed NCT02110108
30 Effect of Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation Following Q-switched Nd:YAG 532 nm Laser for Treatment of Facial Lentigines - A Pilot Study Completed NCT02492373 topical 0.05% Clobetasol propionate ointment
31 A Single-Center 2-Arm Study of the Enlighten and Excel V Laser for Lentigines on the Hands Completed NCT02763072
32 Safety and Efficacy of Cutera Picosecond Q-Switched Nd:YAG Laser in the Treatment of Solar Lentigines Completed NCT01885871
33 A Prospective Multi-Center Study of a Novel Dual-Wavelength, Dual-Pulse Duration Laser for the Treatment of Melasma and Lentigines in Asian Skin Completed NCT02385994
34 Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna Completed NCT00707174 Imiquimod Cream;Tazarotene Cream 0.1%
35 Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy Completed NCT03457246
36 Clinical Evaluation of the Performance of a Difluoroethane-based Cyto-selective Cryotherapy to Treat Dark Spots on the Hand in 30 Volunteers. Completed NCT03157427
37 In Vivo Reflectance Confocal Microscopy for Pigmented Lesion Diagnosis: A Multi-center Study Completed NCT00785369
38 Reflectance Confocal Microscopy to Diagnose Malignant Melanoma and Lentigo Maligna Recruiting NCT03508297
39 Advanced Harmonic Generation Microscopy for Treatment Assessment of Cutaneous Pigmentary Disorder Recruiting NCT03578315
40 Comparative Study of Electrical Impedance Spectroscopy (EIS) Models Against Verified Dermatological Diagnostic Data Recruiting NCT04688749
41 Investigation Into the Natural History and Metabolic and Molecular Basis of RASopathies. Recruiting NCT04395495
42 Histologic Evaluation of Tissue Following Lutronic System Exposure Active, not recruiting NCT04207047
43 The Effect of Topical Anesthetic Using Lidocaine 2.5%/Prilocaine 2.5% Versus Lidocaine 7%/Tetracaine 7% Cream on Patients' Pain and Operative Experience During Treatment With QSwitched 532nm Laser Active, not recruiting NCT02427724 lidocaine 2.5%/prilocaine 2.5% topical anesthetic;lidocaine 7%/tetracaine 7% topical anesthetic;placebo vehicle
44 A Single Center, Randomized, Double-blind and Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of Brightening Micro-needle Patch on Facial Solar Lentigines Enrolling by invitation NCT04583852
45 Open Label, Prospective, Single-Center Pilot Study to Evaluate the Effect of Multiple Passes on Port Wine Stain Treatments With the Cutera Excel V™ Laser. Suspended NCT04103164
46 Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence Withdrawn NCT02306512

Search NIH Clinical Center for Lentigines

Genetic Tests for Lentigines

Anatomical Context for Lentigines

MalaCards organs/tissues related to Lentigines:

40
Skin, Lymph Node, Heart, Bone, Breast, Cervix, Pituitary

Publications for Lentigines

Articles related to Lentigines:

(show top 50) (show all 2478)
# Title Authors PMID Year
1
A pedigree of generalized lentigo. 57 61
15422118 1950
2
A novel PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease and the Carney complex. 54 61
19833579 2010
3
PTPN11 gene mutation and severe neonatal hypertrophic cardiomyopathy: what is the link? 54 61
19582499 2009
4
Heterogeneity of skin manifestations in patients with Carney complex. 54 61
18804312 2008
5
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. 54 61
18470943 2008
6
Polymorphism patterns in the promoter region of the MC1R gene are associated with development of freckles and solar lentigines. 54 61
18079748 2008
7
Effect of Val92Met and Arg163Gln variants of the MC1R gene on freckles and solar lentigines in Japanese. 54 61
17371441 2007
8
PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype". 61 54
16733669 2006
9
Association between endothelin receptor B nonsynonymous variants and melanoma risk. 61 54
16145050 2005
10
A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome. 61 54
15470362 2004
11
Clinical and molecular genetics of primary pigmented nodular adrenocortical disease. 61 54
15761532 2004
12
c-kit Mutation in generalized lentigines associated with gastrointestinal stromal tumor. 54 61
15118370 2004
13
Clinical and molecular genetics of Carney complex. 61 54
12666684 2003
14
PTPN11 mutations in LEOPARD syndrome. 54 61
12161596 2002
15
The melanocortin-1-receptor gene is the major freckle gene. 54 61
11487574 2001
16
Genetics of Peutz-Jeghers syndrome, Carney complex and other familial lentiginoses. 61 54
11595829 2000
17
Xeroderma pigmentosum in Yemen. 61
33538348 2021
18
Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders. 61
33354767 2021
19
Mohs surgery for the treatment of lentigo maligna and lentigo maligna melanoma - a systematic review. 61
31696746 2021
20
Clinical brightening efficacy and safety of Melasolv™ (3,4,5-trimethoxy cinnamate thymol ester, TCTE) in Southeast Asian women. 61
33533074 2021
21
Combination treatment algorithm for pigmentary disorders of the face: A prospective observational study in Asian patients. 61
33046430 2021
22
Diagnostic application of cyclin D1 fluorescent in situ hybridization for histologically undetermined early lesions of acral melanoma in situ: A case series. 61
33341705 2021
23
The dermoscopic inverse approach significantly improves the accuracy of human readers for lentigo maligna diagnosis. 61
32592885 2021
24
Follikulotropismus bei Lentigo maligna und Lentigo-maligna-Melanom im Kopf-Hals-Bereich. 61
33586901 2021
25
Folliculotropism in head and neck lentigo maligna and lentigo maligna melanoma. 61
33166059 2021
26
Immunohistochemical study of CD117 in various cutaneous melanocytic lesions. 61
33363589 2021
27
Association of Mohs Micrographic Surgery vs Wide Local Excision With Overall Survival Outcomes for Patients With Melanoma of the Trunk and Extremities. 61
33084853 2021
28
Reflectance confocal microscopy: Diagnostic criteria of common benign and malignant neoplasms, dermoscopic and histopathologic correlates of key confocal criteria, and diagnostic algorithms. 61
32565210 2021
29
In vivo multimodal optical imaging of dermoscopic equivocal melanocytic skin lesions. 61
33446823 2021
30
Outcomes of Staged Excision With Circumferential en Face Margin Control for Lentigo Maligna of the Head and Neck. 61
32911979 2021
31
Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10 years follow-up at a tertiary centre. 61
33502077 2021
32
May melanophages hinder the subclinical spread of lentigo maligna and lentigo maligna melanoma? Results from a pilot study. 61
33462879 2021
33
Pitfalls in the diagnosis of lentigo maligna and lentigo maligna melanoma, facts and an opinion. 61
33051287 2021
34
Xeroderma Pigmentosum: A Model for Human Premature Aging. 61
33436302 2021
35
Predicting the risk of cardiac myxoma in Carney complex. 61
32893266 2021
36
Treatment of benign hyperpigmentations and pigmented scars by 755 alexandrite laser comparing the Single Pass versus MultiPass (MoveoPL) emission in skin types I-IV. 61
33506629 2021
37
Patient Satisfaction and Management of Postoperative Complications Following Ablative Carbon Dioxide Laser Resurfacing of the Lower Eyelids. 61
33481534 2021
38
Mitochondrial Secrets of Youthfulness. 61
33347072 2021
39
Noonan syndrome with loose anagen hair with variants in the PPP1CB gene: First familial case reported. 61
33491856 2021
40
Identification of a novel mutation in the KITLG gene in a Chinese family with familial progressive hyper- and hypopigmentation. 61
33407466 2021
41
Newborn infant with congenital lentigines as a manifestation of Carney Complex. 61
33414123 2021
42
Multiple lentigines in RASA1-associated capillary malformation-arteriovenous malformation syndrome. 61
33319004 2021
43
Upstaging of melanoma in situ and lentigo maligna treated with Mohs micrographic surgery rarely results in additional surgical management. 61
32002653 2020
44
Basal cell carcinoma colonized by lentigo maligna melanoma, with perineural invasion by both neoplasms. 61
32989833 2020
45
Surgical procedures in melanoma in 2020: recommended deep and lateral margins, indications for sentinel lymph node biopsy, and complete lymph node dissection. 61
33314890 2020
46
A case of adult-onset longitudinal melanonychia due to nail matrix compound nevus. 61
32640104 2020
47
Subtyping Cutaneous Melanoma Matters. 61
33409460 2020
48
Emerging role of dermal compartment in skin pigmentation: comprehensive review. 61
32243635 2020
49
Dermatoscopy of melanoma according to type, anatomic site and stage: a 2020 update. 61
33314891 2020
50
Genotype-phenotype association by echocardiography offers incremental value in patients with Noonan Syndrome with Multiple Lentigines. 61
33318624 2020

Variations for Lentigines

Expression for Lentigines

Search GEO for disease gene expression data for Lentigines.

Pathways for Lentigines

Pathways related to Lentigines according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 RAF1 PRKAR1A BRAF
2
Show member pathways
12.65 RAF1 MC1R BRAF
3
Show member pathways
12.64 RAF1 PRKAR1A BRAF
4
Show member pathways
12.62 RAF1 PTPN11 BRAF
5
Show member pathways
12.61 RAF1 PRKAR1A BRAF
6
Show member pathways
12.55 RAF1 PRKAR1A BRAF
7
Show member pathways
12.52 RAF1 PTPN11 BRAF
8
Show member pathways
12.47 RAF1 PTPN11 BRAF
9
Show member pathways
12.45 RAF1 PTPN11 BRAF
10
Show member pathways
12.4 RAF1 PRKAR1A BRAF
11
Show member pathways
12.4 RAF1 PRKAR1A BRAF
12
Show member pathways
12.34 RAF1 PTPN11 BRAF
13
Show member pathways
12.27 RAF1 PTPN11 PRKAR1A
14
Show member pathways
12.2 RAF1 PTPN11 BRAF
15
Show member pathways
12.03 RAF1 PTPN11 BRAF
16
Show member pathways
12.03 RAF1 PTPN11 PRKAR1A BRAF
17
Show member pathways
12 RAF1 PTPN11 BRAF
18
Show member pathways
11.95 RAF1 PRKAR1A BRAF
19 11.86 RAF1 PTPN11 BRAF
20
Show member pathways
11.82 RAF1 PTPN11 BRAF
21
Show member pathways
11.76 RAF1 BRAF
22 11.75 RAF1 BRAF
23 11.74 RAF1 BRAF
24 11.72 RAF1 BRAF
25
Show member pathways
11.7 RAF1 PTPN11
26 11.69 RAF1 BRAF
27 11.68 RAF1 BRAF
28 11.65 RAF1 PTPN11 BRAF
29
Show member pathways
11.62 RAF1 BRAF
30
Show member pathways
11.62 RAF1 PTPN11
31 11.59 RAF1 BRAF
32 11.55 RAF1 BRAF
33 11.54 RAF1 BRAF
34 11.51 RAF1 BRAF
35
Show member pathways
11.51 RAF1 PTPN11 PRKAR1A
36 11.49 RAF1 BRAF
37
Show member pathways
11.48 RAF1 BRAF
38
Show member pathways
11.45 RAF1 BRAF
39 11.44 RAF1 BRAF
40 11.43 RAF1 BRAF
41 11.43 RAF1 PRKAR1A BRAF
42 11.38 RAF1 BRAF
43 11.34 RAF1 BRAF
44 11.34 RAF1 BRAF
45 11.27 RAF1 PTPN11
46 11.26 RAF1 PTPN11
47
Show member pathways
11.26 RAF1 BRAF
48 11.24 RAF1 BRAF
49 11.21 PRKAR1A MC1R
50 11.16 RAF1 BRAF

GO Terms for Lentigines

Biological processes related to Lentigines according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 platelet activation GO:0030168 9.49 RAF1 PTPN11
2 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.48 RAF1 BRAF
3 somatic stem cell population maintenance GO:0035019 9.46 RAF1 BRAF
4 epidermal growth factor receptor signaling pathway GO:0007173 9.43 PTPN11 BRAF
5 heart development GO:0007507 9.43 RAF1 PTPN11 PRKAR1A
6 thymus development GO:0048538 9.4 RAF1 BRAF
7 activation of MAPKK activity GO:0000186 9.37 RAF1 BRAF
8 thyroid gland development GO:0030878 9.32 RAF1 BRAF
9 neurotrophin TRK receptor signaling pathway GO:0048011 9.16 RAF1 PTPN11
10 face development GO:0060324 8.96 RAF1 BRAF
11 intracellular signal transduction GO:0035556 8.92 RAF1 PRKAR1A MC1R BRAF

Molecular functions related to Lentigines according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAP kinase kinase kinase activity GO:0004709 8.96 RAF1 BRAF
2 mitogen-activated protein kinase kinase binding GO:0031434 8.62 RAF1 BRAF

Sources for Lentigines

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....